Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Novartis
Cerilliant
Julphar
Baxter
McKesson
Argus Health
Fish and Richardson
UBS
US Department of Justice

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,965,525

« Back to Dashboard

Which drugs does patent 5,965,525 protect, and when does it expire?

Patent 5,965,525 protects ERAXIS and is included in one NDA.

This patent has forty-three patent family members in twenty-six countries.
Summary for Patent: 5,965,525
Title: Cyclic peptide antifungal agents
Abstract:Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R and R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
Inventor(s): Burkhardt; Frederick J. (Indianapolis, IN), Debono; Manuel (Indianapolis, IN), Nissen; Jeffrey S. (Indianapolis, IN), Turner, Jr.; William W. (Bloomington, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/449,056
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 5,965,525

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF FUNGAL INFECTIONS ➤ Subscribe
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF FUNGAL INFECTIONS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,965,525

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,790,744 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
5,932,543 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
6,384,013 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
6,916,784 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
6,743,777 Cyclic peptide antifungal agents and process for preparation thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,965,525

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Fuji
Cerilliant
Novartis
Accenture
Express Scripts
Cipla
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot